Sánchez, J. (Javier)

Filtering

20232

Settings

Author search.filters.isAuthorOfPublication.c855568f-1ce6-42d2-a7ac-82abd9a9a106

Search Results

Now showing 1 - 2 of 2
  • Thumbnail Image
    Studying the role of BCL2 and MYC in the pathogenesis of diffuse large B cell lymphoma
    (Universidad de Navarra, 2023-12-14) Sánchez, J. (Javier); Martinez-Climent, J.A. (José Ángel); Roa, S. (Sergio)
    Approximately 30% of patients with diffuse large B-cell lymphoma (DLBCL) co-express BCL2 and MYC, known as double-expressor lymphomas (DEL). These lymphomas associate with poorer prognosis and response to standard-of-care R-CHOP, and a preferred therapeutic alternative has not been identified yet. There are very interesting ongoing clinical trials to evaluate the potential of venetoclax to inhibit the anti-apoptotic protein BCL2 in high grade B cell lymphomas. Additionally, there are investigations ongoing trying to find a MYC inhibitor that can be efficiently used in the clinic without secondary effects. Here, we aimed to provide complementary preclinical in vivo evidences for these investigations, modelling this DEL-scenario in new mouse models and demonstrating that combination of anti-CD20 with BCL2 or MYC specific inhibitors can improve long-term survival in BCL2/MYC-expressor DLBCL mice. For this, we first generated and characterized three multi-transgenic mouse models and further demonstrated that it is possible to successfully recapitulate the complex progression and tumor microenvironment of DEL-DLBCL in the murine setting, recapitulating the classical genetic alterations of these patients by conditional mutagenesis at early stages of the germinal center reaction. We then demonstrated that lymphomas in these mice rapidly acquire aberrant BCL2/MYC co-expression and impair apoptosis during NF-κB-driven malignant transformation of germinal center B cells, hindering DLBCL cells sensitive to inhibition of BCL2 (with venetoclax) or MYC (with MYCi975). Then, we provided in vivo evidences that combination of venetoclax with anti-CD20-based immunotherapy can result in synergistic anti-lymphoma effects and extended overall survival of mice. Not only we demonstrated specific cell killing of BCL2/MYC co-expressing lymphoma cells in response to the combination treatment; but also, we revealed, for the first time in DLBCL, that venetoclax can promote the enrichment of activated intratumoral effector/effector memory CD8+ T cells, exhibiting additional immunomodulatory potential in the DEL-DLBCL tumor microenvironment. In addition, we demonstrated that acceleration of lymphomagenesis was evidenced when MYC expression was enforced from early stages of germinal center reaction. However, this lymphomagenesis was accompanied by the appearance of non-B-cells gastrointestinal tumors, possibly driven by the leakage of MYC expression, hence, resulting resistant to the conventional anti-CD20 immunotherapeutic regimen and to antibiotic treatment, impairing overall survival. Altogether, our results strongly support pre-clinical proof-of-concept and rationale for incorporating venetoclax to anti-CD20-based treatments to improve the outcome of aggressive DEL-DLBCL, and provide evidences for future combinations with specific MYC inhibitors, either incorporating them to the actual gold-standard R-CHOP or by dual targeting the Achilles heels of tumor cells through combined BCL2 and MYC specific inhibition. These preclinical combinations could either be performed in our murine models or in the novel 3D culture technique that we have successfully implemented here, which allows the long-term culture of lymphoma cells with its tumor microenvironment in the form of tumor spheroids and could serve as an ex vivo platform for future screening of novel therapeutic strategies in DLBCL.
  • Thumbnail Image
    Venetoclax improves CD20 immunotherapy in a mouse model of MYC/BCL2 double-expressor diffuse large B-cell lymphoma
    (2023) Contreras-Grijalba, S. (Sara); Blanco, O. (Oscar); Martinez-Climent, J.A. (José Ángel); Sánchez, J. (Javier); Pascual, M. (Marien); Panizo, C. (Carlos); Arnaiz-Leche, A. (Adrian); Segura-Ruiz, V. (Victoriano); Novo-Villaverde, F. J. (Francisco Javier); García-Lacarte, M. (Marcos); Pérez-Galán, P. (Patricia); Garcia-Valero, J. (Juan); Roa, S. (Sergio)
    BackgroundApproximately one-third of diffuse large B cell lymphoma (DLBCL) patients exhibit co-expression of MYC and BCL2 (double-expressor lymphoma, DEL) and have a dismal prognosis. Targeted inhibition of the anti-apoptotic protein BCL2 with venetoclax (ABT-199) has been approved in multiple B-cell malignancies and is currently being investigated in clinical trials for DLBCL. Whether BCL2 anti-apoptotic function represents a multifaceted vulnerability for DEL-DLBCL, affecting both lymphoma B cells and T cells within the tumor microenvironment, remains to be elucidated.MethodsHere, we present novel genetically engineered mice that preclinically recapitulate DEL-DLBCL lymphomagenesis, and evaluate their sensitivity ex vivo and in vivo to the promising combination of venetoclax with anti-CD20-based standard immunotherapy.ResultsVenetoclax treatment demonstrated specific killing of MYC+/BCL2(+) lymphoma cells by licensing their intrinsically primed apoptosis, and showed previously unrecognized immunomodulatory activity by specifically enriching antigen-activated effector CD8 T cells infiltrating the tumors. Whereas DEL-DLBCL mice were refractory to venetoclax alone, inhibition of BCL2 significantly extended overall survival of mice that were simultaneously treated with a murine surrogate for anti-CD20 rituximab.ConclusionsThese results suggest that the combination of anti-CD20-based immunotherapy and BCL2 inhibition leads to cooperative immunomodulatory effects and improved preclinical responses, which may offer promising therapeutic opportunities for DEL-DLBCL patients.